Scientists have found new drugs that can be used to prevent spread of breast tumor

A new study has found that drugs approved for the treatment of estrogen receptor-positive breast cancer have the potential to prevent the spread of refractory triple-negative breast cancer. The study using recombinant horse proteins and published in Nature Communications shows that the drug blocks triple-negative breast cancer in many models by blocking an enzyme pathway called CDK4 / 6 - the CDK4 / 6 inhibitor.

Estrogen Receptor Positive (ER Positive) Breast cancer is one of the most common forms of breast cancer, which contains estrogen receptors. When these receptors receive the hormone signal, it will promote cancer cell growth. Similarly, in progesterone receptor-positive (PR-positive) breast cancer, cancer cells containing progesterone receptors can promote cancer cell growth, whereas HER2-positive breast cancer cells on the HER2 gene receptor may exacerbate the condition. Fortunately, there are some hormones for the treatment of breast cancer and other drugs that can target the role of estrogen, progesterone and HER2 receptors, and CDK4 / 6 inhibitors belong to this category. These drugs have been approved for the treatment of ER and HER2-positive breast cancer.

Now, co-author of the study Dr. Matthew Goetz and colleagues from the Rochester Mayo Clinic Women's Cancer Program believe that the use of CDK4 / 6 inhibitors in the treatment of triple negative breast cancer may be effective. Triple-negative breast cancer cells lack estrogen, progesterone and HER2 receptors. Thus, the cancer does not respond to the treatment of the target targeting these receptors, which makes treatment more difficult. However, the team found that CDK4 / 6 inhibitors can effectively prevent triple-negative breast cancer cells spread to other parts - that is, cancer metastasis.

The study found that CDK4 / 6 inhibitors do not triple negative breast cancer cell growth. These drugs can be targeted by acting on a protein known as SNAIL to significantly reduce the spread of cancer cells to distant organs, and SNAIL can promote cancer Cell transfer. According to the researchers, their findings suggest that CDK4 / 6 inhibitors may be beneficial in triple-negative breast cancer patients.

"These findings may provide a new treatment for preventing cancer metastasis. Meo Clinic is carrying out a new study focusing on the role of CDK4 / 6 inhibitors and may inhibit the presence of women with triple negative breast cancer," Dr. Matthew Goetz says. By the way, Flarebio provides recombinant proteins of high quality including recombinant ITGB2.